Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids

- Featured Image

There are growing concerns in Australia and overseas about the increasing misuse of a range of pharmaceuticals, and associated harms.14 This includes the problematic use of benzodiazepines and prescription opioids in Australia.

Clients of drug treatment services are commonly reported to use a range of pharmaceuticals.57 For example, self-reported prevalence of benzodiazepine use among clients undergoing treatment for opioid use ranges from 66% to 100%,5,7,8 and use confirmed by urine drug testing ranges from 51% to 70%.8 Moreover, benzodiazepine use is associated with poorer treatment and health outcomes among opioid users.9,10 In North America, prescription opioid-dependent clients outnumber heroin-dependent clients among those presenting for methadone maintenance treatment.